Trial · NCT07341958
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage change in Lp(a) from baseline at 90 days. | From baseline to 90 days after randomization | |
| Secondary | Incidence of new stroke (including hemorrhagic and ischemic stroke) within 90 days. | From baseline to 90 days after randomization | Symptoms and signs of acute neurological deficits caused by sudden focal or whole brain, spinal cord or retinal vascular damage, which are related to cerebral circulatory disorders, including hemorrhagic and ischemic stroke |
| Secondary | Incidence of composite clinical endpoint events within 90 days | From baseline to 90 days after randomization | Including recurrent ischemic stroke, myocardial infarction, rehospitalization for unstable angina or heart failure, and cardiovascular death |
| Secondary | Incidence of myocardial infarction within 90 days. | From baseline to 90 days after randomization | Acute myocardial infarction is diagnosed by the third edition of the international general diagnostic criteria (Glob Heart. 2012 Dec;7(4):275-95) |
| Secondary | Incidence of vascular death within 90 days. | From baseline to 90 days after randomization | Vascular death includes stroke, sudden cardiac death, acute myocardial infarction, heart failure, pulmonary embolism, heart / cerebrovascular intervention or surgery (death unrelated to acute MI) and other cardiovascular causes of death \[such as: Arrhythmia irrelevant with sudden cardiac death, aortic aneurysm rupture, or peripheral artery disease. Any death of unknown/unclear cause that occurs within 30 days after stroke, myocardial infarction, or cardio-cerebrovascular operation/surgery will be regarded as death due to stroke, myocardial infarction, or cardio-cerebrovascular operation/surgery, respectively. |
| Secondary | Incidence of all-cause death within 90 days. | From baseline to 90 days after randomization | |
| Secondary | Proportion of patients with poor functional outcome (mRS score 2-6) at 90 days. | From baseline to 90 days after randomization | The Modified Rankin Scale (mRS) score ranges from 0 to 6, with higher scores indicating worse functional outcome. The modified Rankin Scale (mRS)= 2-6: poor functional outcome |
| Secondary | Proportion of patients with Lp(a) <30 mg/dL at 90 days | From baseline to 90 days after randomization | |
| Secondary | Percent reduction in ApoB and LDL-C levels from baseline to 90 days | From baseline to 90 days after randomization | |
| Secondary | LDL-C goal attainment rate (<1.8 mmol/L or reduction ≥ 50%) at 90 days | From baseline to 90 days after randomization | |
| Secondary | Moderate and severe bleeding events (GUSTO classification) | From baseline to 90 days after randomization | The GUSTO classification provides a three-tiered (severe, moderate, mild), criteria-driven framework for consistently reporting bleeding complications in clinical research, with a focus on hemodynamic impact and objective laboratory/transfusion data. |
| Secondary | Hepatotoxicity: Post-treatment ALT or AST levels exceeding 3 times the upper limit of normal upon re-measurement | From baseline to 90 days after randomization | Hepatotoxicity in this context is defined as a confirmed elevation of liver enzymes after treatment. Specifically, it means that a follow-up blood test shows either ALT or AST levels to be more than three times higher than the normal limit. This is a standard safety criterion for detecting potential drug-induced liver injury in clinical trials. |
| Secondary | Muscle toxicity | From baseline to 90 days after randomization | Post-treatment creatine kinase levels exceeding 10 times the upper limit of normal upon re-measurement, or occurrence of skeletal muscle adverse events (myalgia, myopathy, or rhabdomyolysis) |
| Secondary | Upper Respiratory Tract Infection (URTI): | From baseline to 90 days after randomization | Common infections affecting the nose, sinuses, throat, or larynx (e.g., common cold, sinusitis). These are general illnesses, not necessarily treatment-related. |
| Secondary | Urinary Tract Infection (UTI) | From baseline to 90 days after randomization | An infection in any part of the urinary system (bladder, urethra, kidneys). It is monitored as a common potential infection during trials. |
| Secondary | Injection Site Reactions: | From baseline to 90 days after randomization | Including papules, bleeding, discoloration, pain, itching, rash, induration, erythema, swelling, etc., at the injection site |
| Secondary | Allergic Reactions: | From baseline to 90 days after randomization | Undesirable immune system responses to the treatment, ranging from mild (rash, itching) to severe, life-threatening anaphylaxis. |
| Secondary | Other Adverse Events/Serious Adverse Events (AEs/SAEs): | From baseline to 90 days after randomization | Other Adverse Events/Serious Adverse Events (AEs/SAEs): |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07341958/registered